# Efficacy of Amantadine Treatment in COVID-19 Patients

> **NCT04952519** · PHASE3 · TERMINATED · sponsor: **Noblewell** · enrollment: 193 (actual)

## Conditions studied

- Patients With Moderate or Severe COVID-19

## Interventions

- **DRUG:** Amantadine

## Key facts

- **NCT ID:** NCT04952519
- **Lead sponsor:** Noblewell
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-30
- **Primary completion:** 2022-03-10
- **Final completion:** 2022-03-10
- **Target enrollment:** 193 (ACTUAL)
- **Why stopped:** The annual analysis did not show the efficacy of the investigational medicinal product in this application, therefore the study was not continued.
- **Last updated:** 2022-09-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04952519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04952519, "Efficacy of Amantadine Treatment in COVID-19 Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04952519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*